Montelukast for Prevention & Treatment of OHSS

Benha University20 enrolled

Overview

montelukast \& dydrgesteron will be given to cases with suspected or proven ovarian hyperstimulation in one group in comparison with dydrogesteron alone in the other group.

patients with high risk for ovarian hyperstimulation will undergo a freeze-all protocol then montelukast \& dydrgesteron will be given to cases with suspected or proven ovarian hyperstimulation in one group in comparison with dydrogesteron alone in the other group.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

SINGLE

Enrollment

Conditions

Ovarian Hyperstimulation Syndrome

Interventions

dydrgesterone 10 mg( tab)/12hs/14 daysDRUG

Dydrogesterone Oral Tablet 10 mg twice daily for 14 days to be taken from the day of ovum pickup

montelukast 10 mg(tab) oral/24hs/ 7 days dydrgesterone 10 mg( tab) oral/12hs/14 daysCOMBINATION_PRODUCT

montelukast 10 mg(tab) once daily oral for 7 days \& dydrgesterone 10 mg (tab) twice daily oral for 14 days \&

Eligibility

Sex: FEMALEMin age: 20 YearsMax age: 37 Years

Medical Language ↔ Plain English

Inclusion Criteria: * PCOS high responders high numbers of ovum retrieved Exclusion Criteria: * hypersensitivity to any drug components phenylketonuria patients depression liver dysfunction

Locations (1)

Banha University- Hawaa Fertility center

Banhā, Qalyubia Governorate, Egypt

Outcomes

Primary Outcomes

Number of Participants who develop ovarian hyperstimulation syndrome

incidence

Time frame: 0-14 days

Secondary Outcomes

Number of Participants treated of ovarian hyperstimulation syndrome

treatment \& resolution

Time frame: 0-14 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.